SCHEMBL10134867

SCHEMBL10134867

COc1ccccc1NC(=O)c1cncc(Oc2ccccc2)n1

nearest known ligand 0.58

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 2/20 0.58
TSHR P16473 1/20 0.57
KMT2A Q03164 5/20 0.54
MEN1 O00255 4/20 0.54
AHR P35869 1/20 0.54
MAPT P10636 3/20 0.51
P4HTM Q9NXG6 1/20 0.51
STAT3 P40763 1/20 0.50
STAT1 P42224 1/20 0.50
IRAK4 Q9NWZ3 1/20 0.49
ALDH1A1 P00352 2/20 0.48
NPC1 O15118 1/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
CD38 P28907 1/20 0.47
GAA P10253 1/20 0.46
HTT P42858 1/20 0.46
BRAF P15056 1/20 0.46
PKM P14618 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10134862 0.81 POLB (0.51) RAB9ATSHRMAPTALDH1A1NPC1
SCHEMBL10134802 0.79 KMT2A (0.54) KMT2AMEN1AHRMAPTP4HTM
SCHEMBL560068 0.78 ATR (0.61) RAB9AKMT2AMEN1AHRP4HTM
SCHEMBL8498266 0.72 F10 (0.48) RAB9AALDH1A1NPC1HTTBRAF
SCHEMBL12368199 0.71 RAB9A (0.89) RAB9ATSHRKMT2AMEN1MAPT
SCHEMBL19101088 0.71 ATR (0.57) TSHRKMT2AMEN1MAPTALDH1A1
SCHEMBL16489068 0.71 ATR (0.69) RAB9AKMT2AMEN1AHRMAPT
SCHEMBL16489067 0.71 KMT2A (0.54) TSHRKMT2AMEN1AHRMAPT
SCHEMBL4651584 0.71 MEN1 (0.68) RAB9AKMT2AMEN1AHRMAPT
SCHEMBL29510900 0.71 MEN1 (0.68) RAB9AKMT2AMEN1AHRMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8962631-B2 Compounds useful as inhibitors of ATR kinase VERTEX PHARMACEUTICALS INCORPORATED (US) 2015-02-24 US disclosed
US-20120035407-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-02-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120035407-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE ATR, CHEK1, CHEK2 RAB9A 3156/4885TSHR 3133/4885KMT2A 1532/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.